Patents by Inventor Rohit Loomba

Rohit Loomba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR DETERMINATION OF LIVER FIBROSIS
    Publication number: 20220308071
    Abstract: The disclosure provides methods for determining liver fibrosis development, risk and prognosis.
    Type: Application
    Filed: June 13, 2020
    Publication date: September 29, 2022
    Inventors: Edward A. Dennis, Rohit Loomba
  • Methods and compositions for identifying non-alcoholic fatty liver disease
    Patent number: 11105823
    Abstract: The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: August 31, 2021
    Assignee: The Regents of the University of California
    Inventors: Edward A. Dennis, Oswald Quehenberger, Rohit Loomba
  • Differential diagnosis of liver disease
    Patent number: 11035846
    Abstract: The disclosure relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: June 15, 2021
    Assignee: The Regents of the University of California
    Inventors: Rohit Loomba, Oswald Quehenberger, Aaron Armando, Edward A. Dennis
  • DIFFERENTIAL DIAGNOSIS OF LIVER DISEASE
    Publication number: 20200011848
    Abstract: The disclosure relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Inventors: Rohit Loomba, Oswald Quehenberger, Aaron Armando, Edward A. Dennis
  • Differential diagnosis of liver disease
    Patent number: 10422786
    Abstract: The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: September 24, 2019
    Assignee: The Regents of the University of California
    Inventors: Rohit Loomba, Oswald Quehenberger, Aaron Armando, Edward A. Dennis
  • USE OF A MICROBIOME PROFILE TO DETECT LIVER DISEASE
    Publication number: 20190127781
    Abstract: A method to detect liver fibrosis or for the differential diagnosis of non-alchohlic fatty liver disease (NAFLD) in a subject is provided. The method comprises analyzing a biological sample from a subject to determine an intestinal microbiome signature for the subject, and inspecting the intestinal microbiome signature relative to a reference intestinal microbiome signature to detect presence or absence of liver fibrosis.
    Type: Application
    Filed: April 20, 2017
    Publication date: May 2, 2019
    Inventors: Shibu YOOSEPH, Rohit LOOMBA, Karen E. NELSON, Victor SEGURITAN, Weizhong LI, Tao LONG, Niels KLITGORD
  • NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS
    Publication number: 20180155787
    Abstract: Methods, compositions, kits, and systems for characterizing the non-alcoholic fatty liver disease (NAFLD) state of a subject are provided. In some embodiments the methods, compositions, kits, and systems comprise at least one miRNA selected from the differentially expressed miRNAs listed in at least one of Tables 1-4, 10-14, and 28-29. In some embodiments the methods compositions, kits, and systems are for characterizing the nonalcoholic steatohepatitis (NASH) state of the subject, characterizing the occurrence of liver fibrosis in the subject, and/or characterizing the occurrence of hepatocellular ballooning in the subject.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 7, 2018
    Inventors: Martin BEAULIEU, Nelson B CHAU, Vivek KAIMAL, Rohit LOOMBA
  • METHODS AND COMPOSITIONS FOR IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20180031585
    Abstract: The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 1, 2018
    Inventors: Edward A. Dennis, Oswald Quehenberger, Rohit Loomba
  • DIFFERENTIAL DIAGNOSIS OF LIVER DISEASE
    Publication number: 20160305925
    Abstract: The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.
    Type: Application
    Filed: December 9, 2014
    Publication date: October 20, 2016
    Inventors: Rohit Loomba, Oswald Quehenberger, Aaron Armando, Edward A. Dennis